Pharmaceutical Executive Daily: September 24, 2025

Sep 24, 2025, 07:41 PM
Headliner
Share
Subscribe

In today’s Pharmaceutical Executive Daily, we cover the market reaction to Trump’s Tylenol–autism claim, the FDA’s complete response letter to Scholar Rock for its spinal muscular atrophy treatment, and a closer look at the state of evidence linking Tylenol use and autism risk.

Share
Subscribe
Next
Pharmaceutical Executive Daily: September 25, 2025
Top episodes
Healthcare Marketing Strategies for Reaching Diverse Audiences
by Pharmaceutical Executive
Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals
by Pharmaceutical Executive
Key Findings of the NIAGARA and HIMALAYA Trials
by Pharmaceutical Executive